Key result
Permanent pacemaker implantation after TAVI was not associated with 1- or 5-year mortality, whereas pre-existing pacemakers increased 5-year mortality risk (HR 1.4).
Why the study?
Permanent pacemaker implantation is a recognized complication of TAVI, but its long-term prognostic impact remains uncertain.
Does permanent pacemaker implantation after TAVI affect all-cause mortality in TAVI recipients?
Does permanent pacemaker implantation after TAVI affect all-cause mortality in TAVI recipients?
New permanent pacemaker implantation after TAVI does not significantly impact 1- or 5-year mortality, whereas a pre-existing pacemaker is associated with higher long-term mortality.
Background/Objectives: Permanent pacemaker (PM) implantation is a well-recognized complication of transcatheter aortic valve implantation (TAVI), but its long-term prognostic impact remains uncertain. To evaluate the association between PM implantation and all-cause mortality in TAVI recipients. Methods: We performed a post hoc analysis of a prospective single-center TAVI registry (2016–2020). The primary endpoint was all-cause mortality at 1 and 5 years. Cox regression and Kaplan–Meier analyses were applied. Validation was performed using the nationwide AUTHEARTVISIT claims database. Results: Among 1114 consecutive TAVI patients (mean age 81 ± 5.8 years; 49.8% female), 120 (10.8%) had a pre-existing PM (Pre-PM), and 153 (13.7%) received a new PM within 30 days post-TAVI (Post-PM). Post-PM patients were older (p = 0.006), more often male (p < 0.001), had higher Troponin T levels (p = 0.002), more pre-existing right bundle branch block (p < 0.001), and longer QRS duration (p < 0.001) compared to patients without PM. In multivariate analysis, one-year mortality was associated with Troponin T (p = 0.002) and NT-proBNP (p = 0.002) serum levels. Pre- or Post-PM status was not associated with 1-year mortality (p = 0.455, p = 975). However, Pre-PM status was independently associated with 5-year mortality (HR 1.4, 95% CI: 1.0–1.9, p = 0.03), whereas Post-PM status was not (HR 1.2, 95% CI: 0.8–1.6, p = 0.22). Findings were confirmed in the nationwide AUTHEARTVISIT cohort. Conclusions: In this large, real-world TAVI cohort with national validation, Post-PM status was not associated with mortality at 1 or 5 years. By contrast, Pre-PM identified patients at higher long-term risk, possibly reflecting underlying cardiac disease.
No takes yet. Share an insight, caveat, or question.
Lamm et al. (2026) studied this question. Permanent pacemaker implantation after TAVI was not associated with 1- or 5-year mortality, whereas pre-existing pacemakers increased 5-year mortality risk (HR 1.4).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: